SEC Form 4 · accession 0001209191-19-004530
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip D Gregory
Officer — Chief Scientific Officer
Period of report
Jan 16, 2019
Accepted (ET)
Jan 18, 2019 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 16, 2019 | M | 1,400 | $75.60 | A | 28,742 | D | |
| Common StockF2 | Jan 16, 2019 | S | 1,900 | $124.2469 | D | 26,842 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $75.60 | Jan 16, 2019 | M | 1,400 | D | — | Feb 1, 2027 | Common Stock | 1,400 | 29,900 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
- F2The range in prices for the transaction reported on this line was $124.03 to $124.60. The average weighted price was $124.2469. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2018 and in 36 equal monthly installments thereafter.